Search Videos by Topic or Participant
Browse by Series:

Role of Transplant in Acute Myeloid Leukemia

Panelists: Dan Douer, MD, MSK; Richard M. Harris, MD, Cedars Sinai; Jeffrey Lancet, MD, Moffitt; Mark R. Litzow, MD, Mayo Clinic; Leonard S. Sender
Published: Tuesday, Apr 21, 2015
For High-Definition, Click
Traditionally, treatment stratification for acute myeloid leukemia (AML) has been based on age. In general, once a patient reaches the age of 75 years, their ability to safely receive intensive chemotherapy with a reasonable chance of response declines, says Jeffrey Lancet, MD. However, treatment biology is now recognized as playing a major role in prognosis.

Individuals with complex cytogenetics, adverse karyotypes, and specific mutational abnormalities will fare poorly with chemotherapy and should be stratified toward a clinical trial, notes Lancet. Several factors should be considered when assessing a patient with AML, including the chances of cure with chemotherapy alone and whether the individual is eligible for transplant, Raoul Tibes, MD, adds.

In general, patients up to 60 years of age with intermediate or high-risk cytogenetic disease are thought to benefit from transplant. Overall, patients with intermediate or high-risk disease with a sibling donor younger than 60 years should be considered for transplant in first remission, Lancet notes. Current data suggests that patients with AML will benefit the most from a sibling allogeneic transplant. At this time, the role of unrelated or alternative donor transplants is still uncertain.

Conducting minimal residual disease testing prior to transplant may have potential prognostic value for outcomes in AML, Mark R. Litzow, MD, suggests. Lancet adds that molecular genetic risk stratification systems are also starting to affect transplant decisions.
Slider Left
Slider Right
For High-Definition, Click
Traditionally, treatment stratification for acute myeloid leukemia (AML) has been based on age. In general, once a patient reaches the age of 75 years, their ability to safely receive intensive chemotherapy with a reasonable chance of response declines, says Jeffrey Lancet, MD. However, treatment biology is now recognized as playing a major role in prognosis.

Individuals with complex cytogenetics, adverse karyotypes, and specific mutational abnormalities will fare poorly with chemotherapy and should be stratified toward a clinical trial, notes Lancet. Several factors should be considered when assessing a patient with AML, including the chances of cure with chemotherapy alone and whether the individual is eligible for transplant, Raoul Tibes, MD, adds.

In general, patients up to 60 years of age with intermediate or high-risk cytogenetic disease are thought to benefit from transplant. Overall, patients with intermediate or high-risk disease with a sibling donor younger than 60 years should be considered for transplant in first remission, Lancet notes. Current data suggests that patients with AML will benefit the most from a sibling allogeneic transplant. At this time, the role of unrelated or alternative donor transplants is still uncertain.

Conducting minimal residual disease testing prior to transplant may have potential prognostic value for outcomes in AML, Mark R. Litzow, MD, suggests. Lancet adds that molecular genetic risk stratification systems are also starting to affect transplant decisions.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x